However, clinical trials using NHE1 inhibitors as cardioprotective agents during I/R proved to be disappointing and without significant benefits, and they even presented certain risks of increased incidence of stroke when higher doses of some agents were used [1,61,64,71]. Here, SLC9A1 is linked to stroke disorder.